LEADER 03317nam  22006015  450 
001 9910568287503321
005 20251113192153.0
010   $a981-19-0197-X
024 7 $a10.1007/978-981-19-0197-3
035   $a(MiAaPQ)EBC6986733
035   $a(Au-PeEL)EBL6986733
035   $a(CKB)22372173700041
035   $a(OCoLC)1319225603
035   $a(DE-He213)978-981-19-0197-3
035   $a(EXLCZ)9922372173700041
100   $a20220514d2022      u|         0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aBreast Cancer: From Bench to Personalized Medicine /$fedited by Saima Shakil Malik, Nosheen Masood
205   $a1st ed. 2022.
210  1$aSingapore :$cSpringer Nature Singapore :$cImprint: Springer,$d2022.
215   $a1 online resource (534 pages)
225 1 $aBiomedical and Life Sciences Series
311 08$aPrint version: Shakil Malik, Saima Breast Cancer: from Bench to Personalized Medicine Singapore : Springer,c2022 9789811901966 
320   $aIncludes bibliographical references and index.
327   $aModule 1_Overview of Breast Cancer -- Module 2_Cell and Molecular Biology of Breast Cancer-Diagnosis and Prognosis -- Module 3_Breast Cancer Treatment.
330   $aThis book provides detailed information on the etiology, pathogenesis, diagnosis, prognosis, and treatment strategies for breast cancer. The first section of the book presents epidemiology, risk factors, histopathological, immunohistochemistry, and molecular subtypes of breast cancer based on the receptor status. It also discusses the association of breast cancer with other hormone-sensitive cancers. The second section of the book covers cover BRCA1 and BRCA2-associated breast carcinogenesis, early-stage progression of breast cancer, and noninvasive biomarkers for the early detection of breast cancer. It also discusses the role of epigenetic modifications and non-coding RNAs in breast cancer metastasis and explores these as the biomarkers and therapeutic targets for breast cancer therapy. Further, it discusses the role of fibrinolytic mechanisms and circulating tumor cells in breast cancer diagnosis, prognosis, and treatment. The book also provides an update on oral poly(ADP-ribose) polymerase (PARP) inhibitors to treat breast cancer. Finally, it offers potential new options for personalized therapies for breast cancer patients, including optimizing drug dosage and identifying genetic changes associated with cancer symptom occurrence and severity.
410  0$aBiomedical and Life Sciences Series
606   $aCancer
606   $aCancer$xEpidemiology
606   $aCancer$xGenetic aspects
606   $aCancer Biology
606   $aCancer Epidemiology
606   $aCancer Genetics and Genomics
615  0$aCancer.
615  0$aCancer$xEpidemiology.
615  0$aCancer$xGenetic aspects.
615 14$aCancer Biology.
615 24$aCancer Epidemiology.
615 24$aCancer Genetics and Genomics.
676   $a616.9449
702   $aMalik$b Saima Shakil
702   $aMasood$b Nosheen
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910568287503321
996   $aBreast Cancer$92851094
997   $aUNINA